{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:27:58Z","timestamp":1768508878177,"version":"3.49.0"},"posted":{"date-parts":[[2023,10,9]]},"group-title":"Cancer Biology","reference-count":45,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,10,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background &amp; Aims<\/jats:title>\n                  <jats:p>Responses to immunotherapies in hepatocellular carcinoma (HCC) are suboptimal with no biomarkers to guide patient selection. \u201cHumanized\u201d mice represent promising models to address this deficiency but are limited by variable chimerism and underdeveloped myeloid compartments. We hypothesized that expression of human GM-CSF and IL-3 increases tumor immune cell infiltration, especially myeloid-derived cells, in humanized HCC patient-derived xenografts (PDXs).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Material and Methods<\/jats:title>\n                  <jats:p>\n                    NOG (NOD\/Shi-\n                    <jats:italic>scid<\/jats:italic>\n                    \/IL-2R\n                    <jats:sup>null<\/jats:sup>\n                    ) and NOG-EXL (huGM-CSF\/huIL-3 NOG) mice conditioned with Busulfan underwent i.v. injection of human CD34+ cells. HCC PDX tumors were then implanted subcutaneously (SQ) or orthotopically (OT). Following serial blood sampling, mice were euthanized at defined tumor sizes. Tumor, blood, liver, and spleen were analyzed by flow cytometry and immunohistochemistry.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Humanized NOG-EXL mice demonstrated earlier and increased human chimerism compared to humanized NOG mice (82.1% vs 43.8%, p&lt;0.0001) with increased proportion of human monocytes (3.2% vs 1.1%, p=0.001) and neutrophils (0.8% vs 0.3%, p=0.02) in circulation. HCC tumors in humanized NOG-EXL mice had increased human immune cell infiltration (57.6% vs 30.2%, p=0.04), noting increased regulatory T cells (14.6% vs 6.8%, p=0.04), CD4+ PD-1 expression (84.7% vs 32.0%, p&lt;0.01), macrophages (1.2% vs 0.6%, p=0.02), and neutrophils (0.5% vs 0.1%, p&lt;0.0001). No differences were observed in tumor engraftment or growth latency in SQ tumors, but OT tumors required implantation at two rather than four weeks post-humanization for successful engraftment. Finally, utilizing adult bone marrow instead of fetal livers enabled partial HLA-matching to HCC tumors but required more CD34+ cells.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Human GM-CSF and IL-3 expression in humanized mice resulted in features more closely approximating the immune microenvironment of human disease, providing a promising model for investigating critical questions in immunotherapy for HCC.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Impact and Implications<\/jats:title>\n                  <jats:p>This study introduces a unique mouse model at a critical point in the evolution of treatment paradigms for patients with hepatocellular carcinoma (HCC). Immunotherapies have become first line treatment for advanced HCC; however, response rates remain low with no clear predictors of response to guide patient selection. In this context, animal models that recapitulate human disease are greatly needed. Leveraging xenograft tumors derived from patients with advanced HCCs and a commercially available immunodeficient mouse strain that expresses human GM-CSF and IL-3, we demonstrate a novel but accessible approach for modeling the HCC tumor microenvironment.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2023.10.05.561117","type":"posted-content","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T11:00:12Z","timestamp":1696849212000},"source":"Crossref","is-referenced-by-count":0,"title":["Human GM-CSF\/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts"],"prefix":"10.64898","author":[{"given":"Kelley","family":"Weinfurtner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tischfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"McClung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Crainic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Gordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma E.","family":"Furth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erena","family":"Tuzneen Supan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Nadolski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence P.F.","family":"Gade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024110406000663000_2023.10.05.561117v3.1","unstructured":"Author names in bold designate shared co-first authorship"},{"key":"2024110406000663000_2023.10.05.561117v3.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2024110406000663000_2023.10.05.561117v3.3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12818"},{"key":"2024110406000663000_2023.10.05.561117v3.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"issue":"8","key":"2024110406000663000_2023.10.05.561117v3.5","first-page":"1","article-title":"Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","year":"2022","journal-title":"NEJM Evidence"},{"key":"2024110406000663000_2023.10.05.561117v3.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01868-2"},{"key":"2024110406000663000_2023.10.05.561117v3.7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3381"},{"key":"2024110406000663000_2023.10.05.561117v3.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0073-4"},{"key":"2024110406000663000_2023.10.05.561117v3.9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.007"},{"key":"2024110406000663000_2023.10.05.561117v3.10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325918"},{"key":"2024110406000663000_2023.10.05.561117v3.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0033-6"},{"key":"2024110406000663000_2023.10.05.561117v3.12","doi-asserted-by":"crossref","unstructured":"Olson B , Li Y , Lin Y et al. Mouse models for cancer immunotherapy research. Cancer Discov. 2018; 1358\u20131365.","DOI":"10.1158\/2159-8290.CD-18-0044"},{"issue":"1","key":"2024110406000663000_2023.10.05.561117v3.13","first-page":"101960","article-title":"Human and mouse PD-L1: similar molecular structure, but different druggability profiles","volume":"24","year":"2020","journal-title":"iScience"},{"issue":"8","key":"2024110406000663000_2023.10.05.561117v3.14","first-page":"1125","article-title":"B-catenin activation promotes immune escape and resistance to anti-PD-1 in hepatocellular carcinoma","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"key":"2024110406000663000_2023.10.05.561117v3.15","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12591"},{"key":"2024110406000663000_2023.10.05.561117v3.16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2731"},{"key":"2024110406000663000_2023.10.05.561117v3.17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3954"},{"key":"2024110406000663000_2023.10.05.561117v3.18","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.140"},{"key":"2024110406000663000_2023.10.05.561117v3.19","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1365"},{"key":"2024110406000663000_2023.10.05.561117v3.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47104-9"},{"key":"2024110406000663000_2023.10.05.561117v3.21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.1.204"},{"key":"2024110406000663000_2023.10.05.561117v3.22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.10.6477"},{"key":"2024110406000663000_2023.10.05.561117v3.23","doi-asserted-by":"publisher","DOI":"10.1038\/nri3311"},{"key":"2024110406000663000_2023.10.05.561117v3.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.03933.x"},{"key":"2024110406000663000_2023.10.05.561117v3.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.06.006"},{"key":"2024110406000663000_2023.10.05.561117v3.26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103660"},{"key":"2024110406000663000_2023.10.05.561117v3.27","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315201"},{"key":"2024110406000663000_2023.10.05.561117v3.28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-301507"},{"key":"2024110406000663000_2023.10.05.561117v3.29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02082"},{"key":"2024110406000663000_2023.10.05.561117v3.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-249326"},{"key":"2024110406000663000_2023.10.05.561117v3.31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.607282"},{"key":"2024110406000663000_2023.10.05.561117v3.32","unstructured":"huNOG-EXL Model Portfolio. Taconic Biosciences. https:\/\/www.taconic.com\/products\/mouse-rat\/nog-portfolio\/humanized-immune-system-mice\/hunog-exl. Accessed 4\/24\/24."},{"key":"2024110406000663000_2023.10.05.561117v3.33","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31812"},{"key":"2024110406000663000_2023.10.05.561117v3.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2020.12.003"},{"key":"2024110406000663000_2023.10.05.561117v3.35","doi-asserted-by":"crossref","unstructured":"Willis E , Verrelle J , Banerjee E et al. Humanization with CD34-positive hematopoetic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice. Vet Pathol. 2024: 3009858231222216.","DOI":"10.1177\/03009858231222216"},{"key":"2024110406000663000_2023.10.05.561117v3.36","unstructured":"Comparison Guide: huNOG-EXL, NSG-SGM3, and MISTRG. Taconic Biosciences. https:\/\/www.taconic.com\/resources\/comparison-guide-hunog-exl-nsg-sgm3-and-mistrg. Accessed 4\/24\/24."},{"key":"2024110406000663000_2023.10.05.561117v3.37","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2858"},{"key":"2024110406000663000_2023.10.05.561117v3.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(99)00078-8"},{"key":"2024110406000663000_2023.10.05.561117v3.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2009.06.005"},{"key":"2024110406000663000_2023.10.05.561117v3.40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018023887"},{"key":"2024110406000663000_2023.10.05.561117v3.41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.573406"},{"key":"2024110406000663000_2023.10.05.561117v3.42","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.317"},{"key":"2024110406000663000_2023.10.05.561117v3.43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1109769108"},{"key":"2024110406000663000_2023.10.05.561117v3.44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-676452"},{"key":"2024110406000663000_2023.10.05.561117v3.45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006921"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.10.05.561117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:20:59Z","timestamp":1768454459000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.10.05.561117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":45,"URL":"https:\/\/doi.org\/10.1101\/2023.10.05.561117","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.jhepr.2024.101264","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,10,9]]},"subtype":"preprint"}}